University of Minnesota. Driven to Discover.
Of $1.6 billion appropriated, $412 million has been targeted to 131 projects.
Experts made more recommendations about fractional IPV dosing and also discussed issued related to cholera, Ebola, and diphtheria.
About 4% of patients traveled, a potential target for curbing disease spread.
The phase 2 trials will enroll more than 5,000 adults and kids in Guinea and Liberia.
In addition, phase 2 trial of an adenovirus-based vaccine shows it to be safe and immunogenic though protection less than prolonged.
About 7.5% of close contacts tested positive, while another study dissected convalescent plasma use.
"I would view the results . . . in an optimistic light," said lead author Richard Davey after the drug showed more than 90% efficacy.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.